Anti-Mouse C5 Monoclonal Antibody (clone BB5.1) -100 µg (CAT#: CB-P146-AB) Datasheet

Antibody

Monoclonal antibody bb5.1 binds to the fifth component of mouse complement (C5). Complement system is a group of plasma membrane and cell membrane proteins which play a key role in the immune system. All three pathways (classical, alternative and lectin) lead to the cleavage of C3, resulting in the formation of cytolytic membrane attack complex C5b-9. If the activation cascade is allowed to cleave beyond C3 to C3a and C3b, additional C3b molecules bind to the C3 invertase. This results in the production of C5 invertase (c3bbbc3b represents the alternative pathway, c4bc2bc3b represents the classical pathway and lectin pathway). C5 invertase cleaves C5, releasing the potent allergenic peptide C5a and producing c5b. C5b can start the terminal pathway, recruit C6, C7, C8 and C9 to the target surface, and insert the C9 complex into the membrane as a pore (called terminal complement complex). C5a is the most effective anaphylactic toxin. It is a powerful chemokine for neutrophils and monocytes, which can promote the marginalization, extravasation and activation of these cells. Therefore, blocking C5 may require the best inhibition of inflammatory response. At the same time, inhibition of complement cascade of C5 does not damage the formation of C3b through classical and alternative pathways, and retains the conditioning and Solubilization Effects of C3b mediated pathogenic microorganisms and immune complexes.
C5 is synthesized as a single polypeptide chain in liver and exists in serum at the concentration of 50-80 μ M / ml. Before secretion, the molecule is glycosylated and secreted into plasma as a 190 kDa glycoprotein, which consists of a disulfide linked α chain (111 kDa) and a beta chain (75 kDa). In functional complement test, monoclonal antibody bb5.1 precipitated two chains of C5 from normal mouse serum and inhibited C5 dependent hemolysis. In addition, bb5.1 administration completely inhibited the terminal complement activity of mouse antibody-mediated rejection (AMR) during heart and kidney transplantation. In another mouse model, pretreatment and intervention with monoclonal antibody bb5.1 could reduce the development of the disease during Anti MPO IgG induced glomerulonephritis. Bb5.1 protects kidney from ischemia-reperfusion injury by inhibiting cell apoptosis and inflammation. In lupus, anti-IL-10 / anti-C5 (bb5.1) combination therapy can prevent and reduce the effect of humoral immune response.

Infectious diseases, Nephrology